Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEWQ4X)

Drug Name

ABT-639 Drug Info

Synonyms

ABT-639; 1235560-28-7; ABT 639; UNII-0G7D0CQ88I; ABT639; 0G7D0CQ88I; CHEMBL3589557; ABT-639 free base; SCHEMBL400073; GTPL7721; CHEMBL3590674; AGPIHNZOZNKRGT-CYBMUJFWSA-N; MolPort-046-033-584; EX-A1021; BCP17732; BDBM50095309; ZINC113741875; AKOS030526344; SB19105; CS-5515; HY-19721; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 46851313
CAS Number: CAS 1235560-28-7
TTD Drug ID: DMEWQ4X
VARIDT Drug ID: DR01117

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium bicarbonate	DMMU6BJ	Metabolic acidosis	5C73	Approved	[3]
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[4]
Mibefradil	DMU9VDS	Glioblastoma multiforme	2A00.0	Phase 1	[5]
TTA-A8	DMWZCIF	Insomnia	7A00-7A0Z	Preclinical	[6]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[7]
ML218	DM3D21X	Discovery agent	N.A.	Investigative	[8]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[9]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[10]
KYS-05080	DM57BXZ	Discovery agent	N.A.	Investigative	[10]
Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide	DM75SO4	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)	TTZPWGN	CAC1H_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7721).
2	Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
3	Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
4	Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
5	Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
6	Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9.
7	Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
8	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
9	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
10	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
11	Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.